Aug. 25 at 1:36 AM
$AMGN $LLY $NVO $VKTX Eli Lilly’s daily obesity pill, if approved, could still be a viable competitor in the weight loss drug market despite late-stage trial data that disappointed investors.
In the trial, orforglipron caused weight loss that missed Wall Street’s expectations and came below what Novo Nordisk reported for its oral drug in a separate study.
But Eli Lilly’s drug could have a few advantages over Novo Nordisk’s pill, including a lack of dietary restrictions, easier manufacturing and a potentially lower price,
